2.55
-0.04 (-1.73%)
| Previous Close | 2.60 |
| Open | 2.60 |
| Volume | 21,507 |
| Avg. Volume (3M) | 57,559 |
| Market Cap | 78,123,080 |
| Price / Earnings (Forward) | 11.70 |
| Price / Sales | 15.49 |
| Price / Book | 2.20 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Operating Margin (TTM) | -480.61% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 10.70% |
| Total Debt/Equity (MRQ) | 6.48% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | -21.87 M |
| Levered Free Cash Flow (TTM) | -11.00 M |
| Return on Assets (TTM) | -44.34% |
| Return on Equity (TTM) | -84.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | InspireMD Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.17 |
|
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 17.66% |
| % Held by Institutions | 41.59% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Affiance Financial, Llc | 30 Sep 2024 | 183,746 |
| Nottingham Advisors, Inc. | 30 Sep 2024 | 30,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Apr 2025 | Announcement | InspireMD to Announce First Quarter 2025 Financial Results |
| 08 Apr 2025 | Announcement | InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 26 Mar 2025 | Announcement | InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference |
| 12 Mar 2025 | Announcement | InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results |
| 26 Feb 2025 | Announcement | InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results |
| 25 Feb 2025 | Announcement | InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 13 Feb 2025 | Announcement | InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures |
| 04 Feb 2025 | Announcement | InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |